Lung cancer screening in never-smokers shows measurable benefit despite lack of guideline endorsement, with emerging evidence supporting its consideration for individuals at elevated risk. This challenges the assumption that screening protocols designed for smokers do not apply to populations with different etiology patterns.
Key Points
- Never-smokers develop lung cancer at rates warranting screening consideration
- Current guidelines lag behind evidence supporting never-smoker screening protocols
- Risk stratification enables targeted screening without population-wide implementation
Longevity Analysis
The evidence for screening in never-smokers reveals how risk models often lag behind clinical reality, particularly when disease etiology differs from the screened population on which guidelines were based. Effective longevity strategy requires decoding individual risk signals rather than applying one-size protocols—understanding your personal exposure history, genetic susceptibility, and environmental factors determines whether a screening tool designed for one population applies to you. This distinction between guideline-driven care and evidence-informed personalization is fundamental to extending both health span and lifespan.
Original published by Peter Attia MD, by Peter Attia.